- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01596062
Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study) (IDEALE)
Prospective, Multicenter, Randomized, Open-label, Phase 2, Lasting 12 Weeks, Evaluating the Pharmacodynamics, Efficacy and Safety of Basiliximab in de Novo Adult Renal Transplant Patients at Low Risk Receiving Either a Cumulative Dose of Basiliximab of 40 or 80 mg in Combination With Cyclosporine Microemulsion, or a Cumulative Dose of 80 mg of Basiliximab Without Calcineurin Inhibitor, With Additional Follow-up of 12 Weeks
The aims of this study are to extensively study the levels of CD25-Receptors saturation and expression obtained with 2 different doses of Simulect® in combination with Neoral® (i.e to demonstrate that saturation and expression vary according to the dose of Simulect® given), and to study the levels of CD25-Receptors saturation without Neoral® and compare them to the data with Neoral®.
It will be conducted in low risk de novo adult renal transplant recipients until 12 weeks post-transplant, receiving either a cumulative dose of 40 or 80 mg of Simulect® in combination with Neoral®, or a cumulative dose of 80 mg of Simulect® in a calcineurin inhibitor free immunosuppressant therapy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bordeaux Cedex, France, 33076
- Novartis Investigative Site
-
Paris cedex 15, France, 75015
- Novartis Investigative Site
-
Tours Cedex, France, 37044
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients receiving a primary renal graft from a deceased or living, related or unrelated donor and who require basiliximab induction therapy
- Cold ischemia time < 30 hours
Exclusion (Non inclusion) criteria:
- Patients undergoing multi-organ transplantation, including both kidneys, or who have previously undergone organ transplantation, including renal transplantation
- Patients receiving a graft from a non-heart-beating donor
- A-B-O incompatible graft or positive T cell crossmatch
- Patients receiving a graft from an expanded criteria donor according to the UNOS definition (donor older than 60 years or donor aged between 50 and 60 years and presence of at least 2 of the following factors: hypertension, serum creatinine concentration ≥ 132 µmol/mL, cardiovascular cause of death)
- Positive anti-HLA antibodies (Luminex) prior to transplantation
- Patients whose original renal disease was primary focal and segmental hyalinosis or was related to atypical hemolytic uremic syndrome
- EBV-negative patients receiving a graft from an EBV-positive donor (EBV D+R-)
Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Simulect 40mg + Neoral + Myfortic + steroids
A cumulative dose of 40 mg of Simulect® (20mg at Day 0 (D0) and 20mg at Day 4 (D4)+ Neoral® + Myfortic® + corticosteroids
|
Simulect® was provided to the study center in its commercial package containing a powder vial with 20 mg of active product and sterile water for injection.
The solution should be used immediately after reconstitution.
The infusion was prepared by adding at least 50 mL of physiologic or 5% glucose solution to the reconstituted solution (at least 100 mL for 40 mg of Simulect®).
Simulect® was transported and kept in a cold environment (2-8°C) as recommended in the summary of product characteristics (SPC).
Other Names:
Neoral® was provided to the study center in its commercial package as 10, 25, 50 or 100 mg soft capsules in thermoformed blister packs.
Other Names:
Myfortic® was administered orally b.i.d. with a 12-hour interval.
Tablets could be taken either with or outside meals but consistently throughout the study.
To maintain the integrity of the enteric coating, tablets were not to be crushed.
Myfortic® treatment was initiated either preoperatively or within 24 hours post transplantation according to local practice in each center.
Starting dose was to be 2160 mg/day (1080 mg b.i.d.) for at least 2 weeks and for at most 4 weeks.
Patients were then to receive 1440 mg/day (720 mg b.i.d.) until the end of the study.
Myfortic® was administered as concomitant treatment to all patients, using the same regimen for all 3 study groups.
It was provided to the study center in its commercial package as 180 and 360 mg gastro-resistant tablets.
Other Names:
Corticosteroid i.v.
therapy could be administered peri or per operatively according to local practice in each center with the same scheme for each patient in the center.
Oral corticotherapy was to be initiated rapidly, within one week following transplantation, with a minimal dose of 20 mg/day.
Thereafter, the dose was to be decreased according to local practice but oral corticosteroids were to be continued throughout the study with a minimal dose of 5 mg/day.
|
EXPERIMENTAL: Simulect 80mg + Neoral + Myfortic + steroids
A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Neoral® + Myfortic® + corticosteroids
|
Simulect® was provided to the study center in its commercial package containing a powder vial with 20 mg of active product and sterile water for injection.
The solution should be used immediately after reconstitution.
The infusion was prepared by adding at least 50 mL of physiologic or 5% glucose solution to the reconstituted solution (at least 100 mL for 40 mg of Simulect®).
Simulect® was transported and kept in a cold environment (2-8°C) as recommended in the summary of product characteristics (SPC).
Other Names:
Neoral® was provided to the study center in its commercial package as 10, 25, 50 or 100 mg soft capsules in thermoformed blister packs.
Other Names:
Myfortic® was administered orally b.i.d. with a 12-hour interval.
Tablets could be taken either with or outside meals but consistently throughout the study.
To maintain the integrity of the enteric coating, tablets were not to be crushed.
Myfortic® treatment was initiated either preoperatively or within 24 hours post transplantation according to local practice in each center.
Starting dose was to be 2160 mg/day (1080 mg b.i.d.) for at least 2 weeks and for at most 4 weeks.
Patients were then to receive 1440 mg/day (720 mg b.i.d.) until the end of the study.
Myfortic® was administered as concomitant treatment to all patients, using the same regimen for all 3 study groups.
It was provided to the study center in its commercial package as 180 and 360 mg gastro-resistant tablets.
Other Names:
Corticosteroid i.v.
therapy could be administered peri or per operatively according to local practice in each center with the same scheme for each patient in the center.
Oral corticotherapy was to be initiated rapidly, within one week following transplantation, with a minimal dose of 20 mg/day.
Thereafter, the dose was to be decreased according to local practice but oral corticosteroids were to be continued throughout the study with a minimal dose of 5 mg/day.
|
EXPERIMENTAL: Simulect 80mg + Certican + Myfortic + steroids
A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Certican® + Myfortic® + corticosteroids
|
Simulect® was provided to the study center in its commercial package containing a powder vial with 20 mg of active product and sterile water for injection.
The solution should be used immediately after reconstitution.
The infusion was prepared by adding at least 50 mL of physiologic or 5% glucose solution to the reconstituted solution (at least 100 mL for 40 mg of Simulect®).
Simulect® was transported and kept in a cold environment (2-8°C) as recommended in the summary of product characteristics (SPC).
Other Names:
Myfortic® was administered orally b.i.d. with a 12-hour interval.
Tablets could be taken either with or outside meals but consistently throughout the study.
To maintain the integrity of the enteric coating, tablets were not to be crushed.
Myfortic® treatment was initiated either preoperatively or within 24 hours post transplantation according to local practice in each center.
Starting dose was to be 2160 mg/day (1080 mg b.i.d.) for at least 2 weeks and for at most 4 weeks.
Patients were then to receive 1440 mg/day (720 mg b.i.d.) until the end of the study.
Myfortic® was administered as concomitant treatment to all patients, using the same regimen for all 3 study groups.
It was provided to the study center in its commercial package as 180 and 360 mg gastro-resistant tablets.
Other Names:
Corticosteroid i.v.
therapy could be administered peri or per operatively according to local practice in each center with the same scheme for each patient in the center.
Oral corticotherapy was to be initiated rapidly, within one week following transplantation, with a minimal dose of 20 mg/day.
Thereafter, the dose was to be decreased according to local practice but oral corticosteroids were to be continued throughout the study with a minimal dose of 5 mg/day.
Certican® was provided to the study center in its commercial package as 0.75, 0.5 and 0.25 mg tablets in thermoformed blister packs.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Curve (AUC) of CD25 Saturation by Basiliximab From Day 0 to Day 84
Time Frame: Day 84 (Week 12) after transplantation
|
CD25 saturation is the percentage of T cells expressing CD25.
Mean AUC of CD25 was calculated only for patients who received two Simulect® injections.
|
Day 84 (Week 12) after transplantation
|
Saturation Rate of CD25 Antigen Saturation by Basiliximab
Time Frame: Day 0, Day 1, Day 4, Day 6, Day 14, Day 21, Day 28, Day 42, Day 56 and Day 84 (Week 12) post-transplantation
|
CD25 saturation is the percentage of T cells expressing CD25
|
Day 0, Day 1, Day 4, Day 6, Day 14, Day 21, Day 28, Day 42, Day 56 and Day 84 (Week 12) post-transplantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC of Basiliximab Binding to CD25 Receptors From Day 0 to Day 84
Time Frame: Day 84 (Week 12) post-transplantation
|
Mean AUC was calculated only for patients who received two Simulect injections.
|
Day 84 (Week 12) post-transplantation
|
Percentage of T-cells That Bind Basiliximab to CD25 Receptors
Time Frame: Day 0, Day 1, Day 4, Day 6, Day 14, Day 21, Day 28, Day 42, Day 56 and Day 84 (Week 12) post-transplantation
|
This is the percentage of T cells binding basiliximab at all timepoints.
|
Day 0, Day 1, Day 4, Day 6, Day 14, Day 21, Day 28, Day 42, Day 56 and Day 84 (Week 12) post-transplantation
|
Proportion of CD3+, CD4+, CD8+, CD19+ and CD56+ T Cells
Time Frame: Day 0, Day 6, Day 42, Day 84 (Week 12)
|
Cell counts of various subpopulations of T, B and NK lymphocytes (CD3, CD4, CD8, CD19 and CD56) (flow cytometry).
|
Day 0, Day 6, Day 42, Day 84 (Week 12)
|
Percentage of Participants With of Biopsy Proven Acute Rejection (BPAR)
Time Frame: Day 84 (Week 12), Week 24 post-transplantation
|
BPAR is one of the components of treatment failure.
One assessment of efficacy was BPAR.
Renal graft biopsies were performed and the renal tissue was examined to determine if there was acute rejection of the renal transplant.
|
Day 84 (Week 12), Week 24 post-transplantation
|
Percentage of Participants With Biopsy Proven Acute Rejection (BPAR) According to Type and Severity
Time Frame: Day 84 (Week 12), Week 24 post-transplantation
|
Antibody mediated acute rejection: C4d deposition, presence of circulating antidonor antibody, morphologic evidence of acute tissue injury such as acute tubular necrosis-like minimal inflammation or capillary and/or glomerular inflammation and/or thromboses or arterial inflammation.
Cellular acute rejection: acute T-cell mediated rejection Type IA: Significant interstitial infiltration (> 25% of parenchyma) and foci of moderate tubulitis (> 4 mononuclear cells/tubular cross section or group of 10 tubular cells) Type IB: Significant interstitial infiltration (> 25% of parenchyma) and foci of severe tubulitis (> 10 mononuclear cells/tubular cross section or group of 10 tubular cells) Type IIA: Mild to moderate intimal arteritis.
Type IIB: Severe intimal arteritis comprising > 25% of the lumenal area.
Type III: Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation).
|
Day 84 (Week 12), Week 24 post-transplantation
|
Percentage of Participants With of Treatment Failures
Time Frame: Day 84 (Week 12), Week 24
|
Treatment failure was defined either as a BPAR, a graft loss, a death or a loss to follow-up.
An extended treatment failure was also defined including treated borderline lesions, BPAR, graft loss, death or loss to follow-up.
Treated borderline lesions were considered as acute rejection by investigators and DMC experts.
|
Day 84 (Week 12), Week 24
|
Estimated Glomerular Filtration Rate (eGFR) at Day 8 and Week 24
Time Frame: Day 8, Week 24
|
(MDRDa formula) with imputation by last observation carried forward (LOCF)
|
Day 8, Week 24
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Antitubercular Agents
- Antibiotics, Antitubercular
- Calcineurin Inhibitors
- Mycophenolic Acid
- Everolimus
- Basiliximab
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- CCHI621AFR05
- 2010-024231-16 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Transplantation
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)Active, not recruitingKidney Transplantation | Renal Transplantation | Renal Transplant RecipientUnited States
-
Astellas Pharma Korea, Inc.CompletedKidney Transplantation | Renal Transplantation | Stable Renal RecipientsKorea, Republic of
-
University of Oslo School of PharmacyCompletedHeart Transplantation | Renal TransplantationNorway
-
NovartisCompletedOrgan Transplantation, Renal Transplantation
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ TransplantationTerminatedKidney Transplantation | Renal TransplantationUnited States
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedKidney Transplantation | Renal Transplant | Renal Transplantation | Transplant Rejection | Transplant ToleranceUnited States
-
University of North Carolina, Chapel HillMallinckrodtWithdrawnKidney Transplantation | Renal Transplantation | FSGSUnited States
-
Bristol-Myers SquibbCompletedKidney Transplantation | Graft Rejection | Renal TransplantationUnited States
-
Rabin Medical CenterRecruitingRenal TransplantationIsrael
Clinical Trials on Simulect®
-
Drexel University College of MedicineNovartisTerminatedEnd Stage Renal DiseaseUnited States
-
Indiana University School of MedicineCompletedMultiple Myeloma | Non-Hodgkin's Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Anemia, Aplastic | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myelodysplasia | Hemoglobinuria, Paroxysmal | Hodgkin's DiseaseUnited States
-
Novartis PharmaceuticalsCompleted
-
Cerimon PharmaceuticalsCompletedUlcerative ColitisUnited States, Poland, Belgium, United Kingdom, Czech Republic, Russian Federation, Slovakia, Ukraine, India
-
Cerimon PharmaceuticalsPPDTerminatedNon-infectious UveitisUnited States
-
Fort Worth Clinical Sciences Working GroupTCU and UNTHSC School of MedicineNot yet recruitingSARS-CoV2 Infection | Cytokine Storm | SARS-CoV-2 Acute Respiratory Disease
-
Coordinación de Investigación en Salud, MexicoCompletedKidney Transplant Rejection | Kidney Transplant; ComplicationsMexico
-
NovartisCompleted
-
Cerimon PharmaceuticalsTerminated
-
Mario Negri Institute for Pharmacological ResearchNot yet recruiting